Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) have received a consensus rating of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $23.00.
JNP has been the topic of a number of recent analyst reports. HC Wainwright restated a “hold” rating on shares of Juniper Pharmaceuticals in a research note on Friday, May 5th. BMO Capital Markets upgraded shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $31.00 to $34.00 in a research note on Friday, July 14th. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Roth Capital set a $12.00 price target on shares of Juniper Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, May 6th.
Shares of Juniper Pharmaceuticals (NASDAQ JNP) traded down 0.0556% during midday trading on Friday, hitting $4.4975. 9,371 shares of the company traded hands. Juniper Pharmaceuticals has a 52 week low of $3.65 and a 52 week high of $7.15. The company has a 50-day moving average price of $4.93 and a 200-day moving average price of $4.72. The stock has a market capitalization of $48.77 million, a P/E ratio of 5.8107 and a beta of 0.28.
Juniper Pharmaceuticals (NASDAQ:JNP) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.10. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. The business had revenue of $13.96 million for the quarter, compared to analyst estimates of $11.84 million. Analysts anticipate that Juniper Pharmaceuticals will post ($0.51) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2017/08/15/brokerages-set-juniper-pharmaceuticals-inc-jnp-target-price-at-23-00.html.
Several hedge funds have recently added to or reduced their stakes in JNP. JW Asset Management LLC raised its stake in Juniper Pharmaceuticals by 10.0% in the second quarter. JW Asset Management LLC now owns 426,903 shares of the specialty pharmaceutical company’s stock worth $2,156,000 after buying an additional 38,771 shares during the last quarter. Algert Global LLC increased its stake in shares of Juniper Pharmaceuticals by 10.8% in the second quarter. Algert Global LLC now owns 120,035 shares of the specialty pharmaceutical company’s stock worth $606,000 after buying an additional 11,720 shares during the period. Spark Investment Management LLC increased its stake in shares of Juniper Pharmaceuticals by 33.0% in the second quarter. Spark Investment Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock worth $303,000 after buying an additional 14,900 shares during the period. Municipal Employees Retirement System of Michigan purchased a new stake in shares of Juniper Pharmaceuticals during the second quarter worth about $1,192,000. Finally, Acadian Asset Management LLC increased its stake in shares of Juniper Pharmaceuticals by 2.3% in the second quarter. Acadian Asset Management LLC now owns 41,978 shares of the specialty pharmaceutical company’s stock worth $211,000 after buying an additional 941 shares during the period. Hedge funds and other institutional investors own 36.61% of the company’s stock.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
